Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
UBS
Express Scripts
Teva
Queensland Health
McKinsey
Merck
US Department of Justice
Novartis

Generated: January 23, 2018

DrugPatentWatch Database Preview

TEVETEN Drug Profile

« Back to Dashboard

Which patents cover Teveten, and when can generic versions of Teveten launch?

Teveten is a drug marketed by Abbvie and is included in two NDAs.

The generic ingredient in TEVETEN is eprosartan mesylate; hydrochlorothiazide. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eprosartan mesylate; hydrochlorothiazide profile page.

US Patents and Regulatory Information for TEVETEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-004 Dec 22, 1997 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-001 Nov 1, 2001 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-005 Dec 22, 1997 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-006 May 27, 1999 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN HCT eprosartan mesylate; hydrochlorothiazide TABLET;ORAL 021268-002 Nov 1, 2001 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for TEVETEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-004 Dec 22, 1997 ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-006 May 27, 1999 ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-006 May 27, 1999 ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-004 Dec 22, 1997 ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-005 Dec 22, 1997 ➤ Subscribe ➤ Subscribe
Abbvie TEVETEN eprosartan mesylate TABLET;ORAL 020738-005 Dec 22, 1997 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for TEVETEN
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 400 mg and 600 mg ➤ Subscribe 5/10/2010

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
UBS
US Army
Medtronic
Farmers Insurance
Teva
Mallinckrodt
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot